3rd Apr 2014 11:17
LONDON (Alliance News) - Physiomics PLC said Thursday that it is in discussions with pharmaceutical companies about starting the first project to use its Virtual Tumour Clinical platform to predict outcomes for a new pipeline drug.
It will be presenting the first validation of its Virtual Tumour Clinical Platform at the AACR Annual Meeting 2014 in San Diego.
The company will show a comparative study of the preclinical Virtual Tumour platform, a technology that uses a mathematical model used to predict the growth of tumours, with an extended and expanded version called the Virtual Tumour Clinical for prostate combination data.
It says this will show how its new model can "translate the effect of the drug combination from the preclinical situation to the clinic."
Physiomics said that after the technology has been validated for prostate cancer, the next step will be to apply it to other indications.
Shares in Physiomics were trading down 3.3% at 0.145 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Physiomics